Table 1.
Baseline characteristics of combined patient cohort (n = 519) treated for NFPA at University Hospitals Birmingham (UHB) and Beaumont Hospital Dublin between 1999 and 2014. Data presented as number (%) unless otherwise stated. Hormonal status refers to pituitary function at study exit
| Treatment centre | |
| Birmingham | 271 (52·2) |
| Dublin | 248 (47·8) |
| Age at diagnosis (years; median, range) | |
| Male | 57 (18–85) |
| Female | 56 (20–91) |
| Gender distribution | |
| Male | 323 (62·2) |
| Female | 196 (37·8) |
| Duration of follow‐up (years; median, range) | |
| Birmingham | 6·0 (0·5–43) |
| Dublin | 7·0 (0·5–35) |
| Presentation | |
| Visual disturbance | 250 (48·2) |
| Incidental | 81 (15·6) |
| Headache | 48 (9·2) |
| Endocrine dysfunction | 39 (7·5) |
| Apoplexy | 38 (7·3) |
| Unavailable | 63 (12·1) |
| Treatment strategy | |
| Surgery | 470 (90·5) (TSS n = 380; TCS n = 90) |
| Observation alone | 49 (9·5) |
| NFPA immunohistochemistry (n = 470 resected tumours) | |
| Null cell tumour | 281 (69·7) |
| Gonadotrophinoma | 74 (18·3) |
| Silent corticotrophinoma | 22 (5·5) |
| Lactotroph | 7 (1·7) |
| Somatotroph | 6 (1·5) |
| Other/mixed immunostaining | 13 (3·3) |
| Unavailable | 67 |
| RT | 183 (35·3) |
| Birmingham | 115 (42·4) |
| Dublin | 68 (27·4) |
| Prophylactic adjuvant RT | 80 (43·7) |
| RT at NFPA recurrence only | 103 (56·3) |
| RT dose (Gy; median, range) | 45 (45–50·4) |
| GH deficiencya | 325 (65·9) |
| Gn deficiencya | 355 (72·0) |
| ACTH deficiencya | 318 (64·5) |
| TSH deficiencya | 307 (62·3) |
| Diabetes insipidusa | 51 (10·3) |
| HC daily dose (mg; median, range) | 20 (5–50) |
| LT4 daily dose (mcg; median, range) | 100 (25–225) |
| Tumour regrowth | 184 (35·4) |
| Multiple surgeries | 121 (23·3) |
| Deaths | 81 (male n = 54) (15·6) |
| Centre | Birmingham n = 40; Dublin n = 41 |
| Age at death (years; median, range) | 78 (24–92) |
ACTH, adrenocorticotropic hormone; DI, diabetes insipidus; GH, growth hormone; Gn, gonadotropin; HC, hydrocortisone; LT4, levothyroxine; RT, radiotherapy; TCS, transcranial surgery; TSH, thyroid‐stimulating hormone; TSS, transsphenoidal surgery.
a
Complete pituitary function data on 493 patients.